PE20191496A1 - 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas - Google Patents
2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidasInfo
- Publication number
- PE20191496A1 PE20191496A1 PE2019001570A PE2019001570A PE20191496A1 PE 20191496 A1 PE20191496 A1 PE 20191496A1 PE 2019001570 A PE2019001570 A PE 2019001570A PE 2019001570 A PE2019001570 A PE 2019001570A PE 20191496 A1 PE20191496 A1 PE 20191496A1
- Authority
- PE
- Peru
- Prior art keywords
- dihydropyridazine
- oxo
- heteroaryl
- optionally substituted
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- SDPWLJFXLIDJQQ-UHFFFAOYSA-N N-(1-hydroxy-3-methylbutan-2-yl)-6-(4-methylphenyl)-2-(1-methylpyrazol-4-yl)-3-oxopyridazine-4-carboxamide Chemical compound OCC(C(C)C)NC(=O)C=1C(N(N=C(C=1)C1=CC=C(C=C1)C)C=1C=NN(C=1)C)=O SDPWLJFXLIDJQQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Referido a compuestos de 2-heteroaril-3-oxo-2,3- dihidropiridazin-4-carboxamida de la formula (I), en donde R1 es hidroxialquilo-C2-C6 opcionalmente sustituidos; cicloalquilo-C3-C6 opcionalmente sustituido, entre otros; R2 es Cl, Ciano, entre otros; R3 es H, F, Cl o metilo; R4 es H o F; R5 es heteroarilo monociclico opcionalmente sustituido, entre otros; X es CH o N. Un compuesto seleccionado es N-(1-hidroxi-3-metilbutan-2-il)-6-(4-metilfenil)-2-(1-metil-1H-pirazol-4-il)-3-oxo- 2,3-dihidropiridazin-4-carboxamida. Tambien se refiere a un procedimiento para preparar dichos compuestos, compuestos intermedios, una composicion y combinacion farmaceutica que los comprende y el uso de dichos compuestos para el tratamiento o la profilaxis del cancer, afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la senalizacion anormal de AHR, como unico agente o en combinacion con otros ingredientes activos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17155406 | 2017-02-09 | ||
| EP17202882 | 2017-11-21 | ||
| PCT/EP2018/052627 WO2018146010A1 (en) | 2017-02-09 | 2018-02-02 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191496A1 true PE20191496A1 (es) | 2019-10-21 |
Family
ID=61188789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001570A PE20191496A1 (es) | 2017-02-09 | 2018-02-02 | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US11795164B2 (es) |
| EP (1) | EP3580211B1 (es) |
| JP (1) | JP7128826B2 (es) |
| KR (1) | KR102627266B1 (es) |
| CN (3) | CN110678459B (es) |
| AU (1) | AU2018217860B2 (es) |
| BR (1) | BR112019016497A2 (es) |
| CA (1) | CA3052718A1 (es) |
| CL (1) | CL2019002255A1 (es) |
| CO (1) | CO2019008684A2 (es) |
| CR (1) | CR20190364A (es) |
| CU (1) | CU24564B1 (es) |
| CY (1) | CY1124484T1 (es) |
| DK (1) | DK3580211T3 (es) |
| DO (1) | DOP2019000206A (es) |
| EC (1) | ECSP19057713A (es) |
| ES (1) | ES2847162T3 (es) |
| GE (1) | GEP20217281B (es) |
| HR (1) | HRP20210143T1 (es) |
| HU (1) | HUE053191T2 (es) |
| IL (1) | IL268469B (es) |
| JO (1) | JOP20190193A1 (es) |
| LT (1) | LT3580211T (es) |
| MA (1) | MA47447B1 (es) |
| MX (1) | MX2019009571A (es) |
| NI (1) | NI201900085A (es) |
| PE (1) | PE20191496A1 (es) |
| PH (1) | PH12019501846A1 (es) |
| PL (1) | PL3580211T3 (es) |
| RS (1) | RS61401B1 (es) |
| SA (1) | SA519402422B1 (es) |
| SG (1) | SG11201907232XA (es) |
| SI (1) | SI3580211T1 (es) |
| TW (1) | TWI770113B (es) |
| UA (1) | UA124507C2 (es) |
| UY (1) | UY37606A (es) |
| WO (1) | WO2018146010A1 (es) |
| ZA (1) | ZA201905902B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190193A1 (ar) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| CN109813913B (zh) * | 2019-01-31 | 2021-11-09 | 中国医学科学院肿瘤医院 | 芳烃受体(AhR)在预测免疫治疗效果中的应用 |
| EP3715471A1 (en) | 2019-03-29 | 2020-09-30 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Ahr signature marker set |
| EP3721894A1 (en) | 2019-04-10 | 2020-10-14 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) as a biomarker and uses thereof |
| CN112724256B (zh) * | 2019-10-28 | 2022-09-16 | 中国农业大学 | 一种高稳定性的磺胺类药物抗体hAb 4D11及其应用 |
| EP3835432A1 (en) | 2019-12-10 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Interleukin-4-induced gene 1 (il4i1) and respective metabolites as biomarkers for cancer |
| KR20220128622A (ko) * | 2019-12-16 | 2022-09-21 | 바이엘 악티엔게젤샤프트 | Ahr-억제제 및 pd1-억제제 항체의 조합물 및 암 치료에서의 그의 용도 |
| EP4110778A1 (en) | 2020-02-26 | 2023-01-04 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| EP4126839A4 (en) * | 2020-03-27 | 2024-04-17 | Dong A St Co Ltd | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114369097B (zh) * | 2020-10-15 | 2023-07-14 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| CN114539221A (zh) * | 2020-11-27 | 2022-05-27 | 苏州泽璟生物制药股份有限公司 | 氘代2-芳杂环-3-氧-2,3-二氢哒嗪-4-甲酰胺类抑制剂及其制备方法和应用 |
| CN114685426A (zh) * | 2020-12-28 | 2022-07-01 | 苏州泽璟生物制药股份有限公司 | 磺酰胺类抑制剂及其制备方法和应用 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| AU2022345008A1 (en) * | 2021-09-14 | 2024-04-04 | Allianthera (Suzhou) Biopharmaceutical Co., Ltd. | 2-aryl or heteroaryl-3-oxo-4-carbamide-6-cyclic-dihydropyrazine aryl hydrocarbon receptor modulators and their use in the treatment of diseases and disorders |
| US20230190961A1 (en) | 2021-10-20 | 2023-06-22 | University Of Rochester | Compositions and methods for treating myelin deficiency by rejuvenating glial progenitor cells |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| JP2000119257A (ja) * | 1998-08-14 | 2000-04-25 | Nippon Nohyaku Co Ltd | ピリダジノン誘導体 |
| WO2000009488A1 (fr) * | 1998-08-14 | 2000-02-24 | Nihon Nohyaku Co., Ltd. | Derives de pyridazinone |
| EP1319659B1 (en) | 2000-09-18 | 2009-03-11 | Eisai R&D Management Co., Ltd. | Triazinones and medicinal use thereof |
| FR2847253B1 (fr) * | 2002-11-19 | 2007-05-18 | Aventis Pharma Sa | Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant |
| WO2007058392A1 (ja) | 2005-11-21 | 2007-05-24 | Japan Tobacco Inc. | ヘテロ環化合物およびその医薬用途 |
| WO2008080056A2 (en) * | 2006-12-21 | 2008-07-03 | Sloan-Kettering Institute For Cancer Research | Pyridazinones and furan-containing compounds |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| WO2012015914A2 (en) | 2010-07-27 | 2012-02-02 | Trustees Of Boston University | Aryl hydrocarbon receptor (ahr) modifiers as novel cancer therapeutics |
| US20170173008A1 (en) | 2014-03-19 | 2017-06-22 | President And Fellows Of Harvard College | Antimicrobial agents and screening methods |
| MX2018014443A (es) * | 2016-05-25 | 2019-04-15 | Bayer Pharma AG | 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas. |
| JOP20190193A1 (ar) | 2017-02-09 | 2019-08-08 | Bayer Pharma AG | ممركبات 2-أريل غير متجانس-3-أكسو-2، 3-ثنائي هيدرو بيريدازين-4-كربوكساميد لمعالجة السرطان |
| US11459312B2 (en) * | 2017-11-21 | 2022-10-04 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
-
2017
- 2017-06-16 JO JOP/2019/0193A patent/JOP20190193A1/ar unknown
-
2018
- 2018-02-02 EP EP18703958.1A patent/EP3580211B1/en active Active
- 2018-02-02 CN CN201880024008.8A patent/CN110678459B/zh active Active
- 2018-02-02 MX MX2019009571A patent/MX2019009571A/es unknown
- 2018-02-02 RS RS20210096A patent/RS61401B1/sr unknown
- 2018-02-02 GE GEAP201815183A patent/GEP20217281B/en unknown
- 2018-02-02 CA CA3052718A patent/CA3052718A1/en active Pending
- 2018-02-02 PL PL18703958T patent/PL3580211T3/pl unknown
- 2018-02-02 WO PCT/EP2018/052627 patent/WO2018146010A1/en unknown
- 2018-02-02 SI SI201830192T patent/SI3580211T1/sl unknown
- 2018-02-02 CN CN202310479983.0A patent/CN116531380A/zh active Pending
- 2018-02-02 PE PE2019001570A patent/PE20191496A1/es unknown
- 2018-02-02 AU AU2018217860A patent/AU2018217860B2/en active Active
- 2018-02-02 MA MA47447A patent/MA47447B1/fr unknown
- 2018-02-02 JP JP2019542502A patent/JP7128826B2/ja active Active
- 2018-02-02 CU CU2019000073A patent/CU24564B1/es unknown
- 2018-02-02 CN CN202310485656.6A patent/CN116554152A/zh active Pending
- 2018-02-02 LT LTEP18703958.1T patent/LT3580211T/lt unknown
- 2018-02-02 CR CR20190364A patent/CR20190364A/es unknown
- 2018-02-02 DK DK18703958.1T patent/DK3580211T3/da active
- 2018-02-02 UA UAA201909559A patent/UA124507C2/uk unknown
- 2018-02-02 KR KR1020197025958A patent/KR102627266B1/ko active IP Right Grant
- 2018-02-02 SG SG11201907232XA patent/SG11201907232XA/en unknown
- 2018-02-02 BR BR112019016497A patent/BR112019016497A2/pt unknown
- 2018-02-02 HU HUE18703958A patent/HUE053191T2/hu unknown
- 2018-02-02 ES ES18703958T patent/ES2847162T3/es active Active
- 2018-02-05 TW TW107104035A patent/TWI770113B/zh active
- 2018-02-09 UY UY0001037606A patent/UY37606A/es unknown
-
2019
- 2019-08-04 IL IL268469A patent/IL268469B/en unknown
- 2019-08-08 PH PH12019501846A patent/PH12019501846A1/en unknown
- 2019-08-08 SA SA519402422A patent/SA519402422B1/ar unknown
- 2019-08-09 CO CONC2019/0008684A patent/CO2019008684A2/es unknown
- 2019-08-09 CL CL2019002255A patent/CL2019002255A1/es unknown
- 2019-08-09 DO DO2019000206A patent/DOP2019000206A/es unknown
- 2019-08-09 NI NI201900085A patent/NI201900085A/es unknown
- 2019-08-12 EC ECSENADI201957713A patent/ECSP19057713A/es unknown
- 2019-09-06 ZA ZA2019/05902A patent/ZA201905902B/en unknown
-
2021
- 2021-01-27 HR HRP20210143TT patent/HRP20210143T1/hr unknown
- 2021-01-28 CY CY20211100070T patent/CY1124484T1/el unknown
-
2022
- 2022-08-12 US US17/819,602 patent/US11795164B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191496A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas | |
| UY38076A (es) | Derivados de tetrahidroquinazolina útiles como agentes anticáncer | |
| UY38070A (es) | Derivados de quinazolina y piridopirimidina sustituidos útiles como agentes anticáncer | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| CO2017001035A2 (es) | “2-(morfolin-4-il)-1,7-naftiridinas sustituidas, composiciones y combinaciones farmacéuticas que las comprenden, y compuestos intermediarios | |
| ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| DOP2018000268A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| CO2017003838A2 (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CU20170077A7 (es) | Compuesto derivado de benzamida sustituida con 1,3-tiazol-2-ilo útil para el tratamiento de trastornos neurogénicos, composiciones y combinaciones que lo comprende | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| DOP2016000208A (es) | Benzimidazol-2-aminas como inhibidores de midh1 | |
| CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
| PE20142456A1 (es) | COMPUESTOS DE OXAZOLIDIN-2-ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks | |
| PE20160167A1 (es) | Composiciones y metodos para alterar la senalizacion del segundo mensajero | |
| UY32483A (es) | Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| ECSP18024565A (es) | Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas | |
| DOP2016000268A (es) | Compuestos de azol amidosustituidos como inhibidores de tnks1 y/o tnks2 | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| NI201700078A (es) | Pirazolpiridinaminas | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| PE20171348A1 (es) | Compuestos de benzoxaborol 4-sustituidos y uso de los mismos | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 |